INTRODUCTION {#s1}
============

Ovarian cancer (OC), leading cause of gynaecologic cancer death, is the second most common gynaecologic cancer \[[@R1]\]. OC is mainly classified into four subtypes: serous, endometrioid, mucinous, and clear cell. Most of malignant OCs are of epithelial origin \[[@R2]\]. To date, the pathogenesis of OC still remains unclear. Multiple factors including age, family history of OC, gravidity, genetic and other environmental factors might be account for the etiology of OC \[[@R3], [@R4]\]. The known ovarian cancer susceptibility genes explain nearly 40% of the excess familial risk of OC \[[@R5]\].

DNA repair system takes part in maintaining the genomic integrity. The repair process usually contains two stages: the excision of lesion and the repair synthesis \[[@R6]\]. The repair system acts by mismatch repair (MMR), nucleotide excision repair (NER), and base-excision repair (BER). The repair by recombination removes a host of serious DNA lesions, encompassing double-stranded breaks (DSBs). These breaks induce a loss of some chromosomes and causes translocation of genetic material between them. Studies provided evidence to support the association between DSBs repair gene variants and ovarian cancer \[[@R7], [@R8]\]. The X-ray cross-complementing (XRCC) genes are DNA repair genes. These genes are associated with the DNA damage processing and genetic stability \[[@R9]\]. Studies have demonstrated that XRCC2 gene participates in homologous recombination of DNA \[[@R10]\]. Excision repair cross-complimentary group 2 (ERCC2), called xeroderma pigmentosum complementation group D (XPD), is involved in the NER pathway. ERCC2 removes certain DNA cross-links, ultraviolet photolesions, and bulky chemical adducts \[[@R11]\]. We hypothesized that those DNA repair genes (XRCC2 and ERCC2) are significantly associated with the risk of OC.

A number of studies \[[@R6], [@R9], [@R11]--[@R18]\] investigated the relationship between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC susceptibility, but with conflicting results. Thus, we conducted a comprehensive meta-analysis to explore the possible association between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk.

RESULTS {#s2}
=======

Characteristics of the included studies {#s2_1}
---------------------------------------

We yielded 97 citations after initial searching. 34 citations were removed after removing duplicates. After screening the titles and abstracts, 36 citations were excluded. 27 citations were selected for further full text review. 16 citations were excluded: 6 were meta-analyses \[[@R19]--[@R24]\]; 6 not case-control studies \[[@R25]--[@R30]\]; 3 investigated other polymorphisms \[[@R14], [@R31], [@R32]\]; 1 did not provide detailed genotyping data \[[@R33]\]. We finally included 11 eligible citations \[[@R6], [@R9], [@R11]--[@R18]\] including 15 studies (4,757 cases and 8,431 controls) in this meta-analysis. Selection for eligible studies included in this meta-analysis was presented in Figure [1](#F1){ref-type="fig"}. The characteristics of included studies are summarized in Table [1](#T1){ref-type="table"}. The Newcastle-Ottawa Scale (NOS) scores of all included studies ranged from 5 to 7 scores.

![Selection for eligible citations included in this meta-analysis](oncotarget-07-86621-g001){#F1}

###### Characteristics of included studies

  Author and year       Country     Genotype method   SOC   Ethnicity   Case      Control   HWE       NOS                               
  --------------------- ----------- ----------------- ----- ----------- --------- --------- --------- --------- --------- --------- --- ---
  Auranen_2005a         UK          TaqMan            PB    Caucasian   629       98        2         704       129       9         Y   6
  Auranen_2005b         Denmark     PCR               PB    Caucasian   260       54        1         331       68        5         Y   6
  Auranen_2005c         USA         PCR               PB    Caucasian   238       31        0         484       75        2         Y   7
  Auranen_2005d         UK          PCR               PB    Caucasian   251       23        1         1538      267       6         Y   6
  Webb_2005a            Australia   PCR-RFLP          HB    Caucasian   364       63        3         802       140       8         Y   5
  Webb_2005b            Australia   PCR-RFLP          HB    Mixed       87        5         2         150       16        2         Y   7
  Beesley_2007          Australia   MALDI-TOF         PB    Caucasian   799       117       7         696       115       7         Y   6
  Mohamed_2013          Egypt       PCR               HB    Caucasian   6         58        36        16        60        24        N   6
  Michalska_2016        Poland      PCR-RFLP          PB    Caucasian   120       80        500       180       400       120       N   7
  **ERCC2 rs13181**                                                     Lys/Lys   Lys/Gln   Gln/Gln   Lys/Lys   Lys/Gln   Gln/Gln       
  Costa_2007            Portugal    PCR-RFLP          HB    Caucasian   55        49        22        95        95        12        Y   7
  Bernard-Gallon_2008   France      TaqMan            HB    Caucasian   1         31        19        119       446       430       Y   5
  Jakubowska_2010       Poland      PCR               HB    Caucasian   58        65        22        100       123       57        Y   6
  Mohamed_2013          Egypt       PCR               HB    Caucasian   32        54        14        55        35        10        Y   7
  Monteiro_2014         Brazil      PCR-RFLP          HB    Caucasian   33        36        1         37        30        3         Y   6
  Michalska_2015        Poland      PCR-RFLP          PB    Caucasian   62        64        304       96        240       94        Y   6

SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE, Hardy--Weinberg equilibrium; NOS, Newcastle-Ottawa Scale

Quantitative synthesis {#s2_2}
----------------------

As presented in Table [2](#T2){ref-type="table"}, we obtained no significant association between XRCC2 rs3218536 or ERCC2 rs13181 (dominant: OR, 1.45; 95% CI, 0.99--2.14, *P* = 0.058, Figure [2](#F2){ref-type="fig"}) polymorphisms and the risk of OC. Stratification analyses were conducted according to HWE status, ethnicity and source of control (SOC). Our data indicated that XRCC2 rs3218536 polymorphism was significantly associated with a decreased risk of OC among HWE positive studies (Table [3](#T3){ref-type="table"}). Regarding stratification analysis by SOC, we detected ERCC2 rs13181 polymorphism increased the risk of OC in population-based study (dominant model, Figure [3](#F3){ref-type="fig"}), while no association was found in both population-based and hospital-based studies. No significant association was obtained about rs3218536 polymorphism when performing stratification analyses by ethnicity.

###### Meta-analysis of association between ERCC2 rs13181, XRCC2 rs3218536 polymorphisms and OC risk

  Genetic models   OR(95%CI)         *P*-value   *P* for heterogeneity   I^2^ (%)   Model
  ---------------- ----------------- ----------- ----------------------- ---------- --------
  **rs13181**                                                                       
  Allele           1.45(0.83,2.54)   0.188       \< 0.001                93.8       Random
  Dominant         1.45(0.99,2.14)   0.058       0.010                   66.7       Random
  Recessive        1.56(0.49,4.93)   0.447       \< 0.001                95.0       Random
  **rs3218536**                                                                     
  Allele           1.05(0.61,1.82)   0.852       \< 0.001                96.4       Random
  Dominant         0.96(0.74,1.24)   0.759       \< 0.001                75.0       Random
  Recessive        1.11(0.34,3.63)   0.862       \< 0.001                91.7       Random
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###### Summary of the subgroup analyses in this meta-analysis

  Comparison      Category    Category    Studies   OR (95% CI)        *P*-value
  --------------- ----------- ----------- --------- ------------------ -----------
  **rs3218536**                                                        
  Allele          SOC         PB          6         1.04(0.49,2.19)    0.926
                              HB          3         1.13(0.77,1.66)    0.535
                  HWE         Positive    7         0.84(0.74,0.95)    0.006
                              Negative    2         2.57(1.03,6.38)    0.042
                  Ethnicity   Caucasian   8         1.08(0.61,1.94)    0.783
                              Asian       1         0.79(0.35,1.78)    0.577
  Dominant        SOC         PB          6         0.91(0.67,1.24)    0.556
                              HB          3         1.17(0.59,2.33)    0.649
                  HWE         Positive    7         0.83(0.73,0.95)    0.007
                              Negative    2         1.74(1.36,2.24)    \<0.001
                  Ethnicity   Caucasian   8         0.98(0.75,1.28)    0.887
                              Asian       1         0.67(0.27,1.67)    0.390
  Recessive       SOC         PB          6         0.92(0.15,5.80)    0.932
                              HB          3         1.57(0.92,2.69)    0.098
                  HWE         Positive    7         0.69(0.37,1.26)    0.225
                              Negative    2         4.74(0.73,30.96)   0.104
                  Ethnicity   Caucasian   8         1.05(0.29,3.73)    0.943
                              Asian       1         1.80(0.25,13.02)   0.558
  **rs13181**                                                          
  Allele          SOC         HB          5         1.19(0.89,1.59)    0.248
                              PB          1         3.61(2.93,4.45)    \<0.001
  Dominant        SOC         HB          5         1.41(0.86,2.32)    0.168
                              PB          1         1.71(1.20,2.43)    0.003
  Recessive       SOC         HB          5         1.13(0.58,2.19)    0.726
                              PB          1         8.62(6.33,11.75)   \<0.001

![Stratification analyses by source of control between ERCC2 rs13181 polymorphism and OC risk (Dominant model)](oncotarget-07-86621-g003){#F3}

We assessed sensitivity by omitting each study once at a time in every genetic model for XRCC2 rs3218536 or ERCC2 rs13181 polymorphisms. The pooled ORs for the effects about these two polymorphisms indicated that our data about the two SNPs were stable and trustworthy (rs3218536: recessive model, Figure [4](#F4){ref-type="fig"}; rs13181: dominant model, Figure [5](#F5){ref-type="fig"}). Begg\'s test was used to evaluate the publication bias of this meta-analysis (rs3218536, allele: *P* = 0.764, dominant: *P* = 1.000, and recessive: *P* = 0.532; rs13181, allele: *P* = 0.573, dominant: *P* = 0.348, and recessive: *P* = 0.851). Our data revealed that there was no obvious publication bias for the two SNPs. Due to significant between-study heterogeneity among some genetic models, we conductedmeta-regression to explore whether ethnicity, HWE status and SOCwere the resources of heterogeneity. However, our data suggested that ethnicity, HWE status and SOC did not seem to be responsible for the heterogeneity (data not shown).
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DISCUSSION {#s3}
==========

DNA repair systems are important for protecting against mutations and are necessary for maintaining the integrity of the genome. Many identified DNA repair genes are recognized to have genetic variations in humans \[[@R34]\]. DNA repair gene polymorphisms may alter the protein function. They can also cause reduction in DNA repair capacity, which may result in genetic instability and carcinogenesis \[[@R35], [@R36]\]. DNA damage influences mitosis and the isolation of chromosomes, which can be solved by homologous recombination repair (HRR) \[[@R37]\]. HRR is a pivotal pathway to repair the DSBs and maintain the genetic stability \[[@R38]\]. XRCC2 is involved in the HRR pathway and associated with DNA DSB repair and genomic stability \[[@R38], [@R39]\]. ERCC2 is one of seven nucleotide excision repair enzymes. ERCC2 could cause Xeroderma Pigmentosum when mutated in germ line. ERCC2 is involved in DNA repair, specifically in nucleotide excision repair. It functions in various types of DNA lesions \[[@R12]\]. Both XRCC2 and ERCC2 are identified as DNA repair genes.

A host of studies \[[@R6], [@R9], [@R11]--[@R18]\] have explored the associations between XRCC2 rs3218536 or ERCC2 rs13181 gene polymorphisms and OC risk. But they provided inconsistent results. These studies were conflicting and inconclusive may due to different ethnic populations, clinical heterogeneity, and small sample sizes. As a result, we conducted a meta-analysis to investigate the association. We found no evidence for an association with XRCC2 rs3218536 or ERCC2 rs13181 polymorphism. Stratification analyses of HWE status revealed that XRCC2 rs3218536 polymorphism was significantly associated with a decreased risk of OC in analysis of HWE positive studies. Studies conform to HWE, indicating control subjects were representative of the general population. Studies with deviation from HWE are prone to false positive results \[[@R40]\]. Further investigations are urgent to confirm the findings of stratification analyses.

Previous meta-analysis \[[@R20], [@R23]\] demonstrated the association with XRCC2 rs3218536 polymorphism, but with contradictory conclusions. Shi et al. found rs3218536 polymorphism reduced the risk of OC \[[@R23]\], while Zhai et al. indicated this SNP increased the risk of ovarian cancer \[[@R20]\]. However, our data suggested that this SNP was not associated with the risk of OC. Compared with previous meta-analysis, this meta-analysis included a new Polish study containing 700 cases and 700 controls. It is well recognized that the association between SNPs in genes with diseases is greatly affected by the number of subjects. Our study has larger sample size, indicating that our data are more robust. Stratification analyses of rs3218536 polymorphism by ethnicity suggested that no association was obtained with Caucasian population or mixed population.

To seek the sources of high heterogeneity in this meta-analysis, we conducted meta-regression analysis, stratification analyses, and sensitivity analysis. Meta-regression analysis of ethnicity, HWE status and SOC was conducted. Our data confirmed that ethnicity, HWE status and SOC were not the sources of heterogeneity. Sensitivity analysis about XRCC2 rs3218536 polymorphism indicated the Polish study \[[@R6]\] may be the source of heterogeneity. We found the heterogeneity reduced substantially in three genetic models (Allele, I^2^ = 48.9%; Dominant, I^2^ = 42.0%); Recessive, I^2^ = 19.6%) when we excluded this Polish study. The reasons of high heterogeneity may due to different ethnic populations, clinical heterogeneity, and small sample sizes.

However, potential limitations should be addressed in this meta-analysis. First, due to limited data, we could not perform further stratification analyses of other populations, such as Asians. Second, our results were based on unadjusted estimates for confounding factors, which might influence the final findings. Third, we could not assess potential gene-gene and gene-environment interactions. Fourth, the sample sizes of subgroup analysis are limited. These stratification analyses were based on small numbers and any association is likely to be due to chance. Fifth, high heterogeneity existed in some genetic models of this meta-analysis.

In summary, this meta-analysis suggests that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with OC susceptibility. Stratification analysis indicates that XRCC2 rs3218536 polymorphism was significantly associated with a decreased risk of OC when in analysis of HWE positive studies. Further studies are necessary to validate whether these two SNPs is associated with OC susceptibility in other ethnic groups.

MATERIALS AND METHODS {#s4}
=====================

Literature search and inclusion criteria {#s4_1}
----------------------------------------

We systematically searched the PubMed, and Embase to identify studies through September 13, 2016. The following search terms were used: "ovarian cancer," "ovarian neoplasm," "ovarian carcinoma," "ERCC2," "XPD," "XRCC2" and "polymorphism". Other potential omitted studies were identified by hand screening. The inclusion criteria of studies were as following: (1) studies that evaluated the association between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk, (2) study provided sufficient data to calculate the odds ratios (ORs) and 95% confidence intervals (CIs), and (3) case-control study.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Data was extracted from all eligible studies by two authors. The extracted information from all eligible studies including: name of first author, publication year, country, ethnicity, source of control, and genotype numbers of cases and controls. Two authors independently conducted the extraction of data. We assessed the study quality according to the NOS \[[@R41]\]. All disagreements were resolved by discussion until reaching consent.

Statistical analysis {#s4_3}
--------------------

The crude ORs and 95%CIs were used to assess the strength of associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analysis was carried out by HWE status, ethnicity and SOC. When a Q test indicated *P* \< 0.1 or I^2^ \> 50% indicated heterogeneity across studies, a random-effect model was used. Otherwise, the fixed-effects model was applied \[[@R42]\]. Pooled ORs were calculated for allele model, dominant model, and recessive model. We performed leave-one-out sensitivity analysis to evaluate the stability of the overall results. We assessed the departure from the HWE in the controls using Pearson\'s χ2 test. Begger\'s linear regression test was used to detect the potential publication bias \[[@R43]\]. Meta-regression analysis of ethnicity, HWE status and SOC was performed to seek the main sources of the heterogeneity. All statistical analyses were performed using the Stata 11.0 software (STATA Corporation, College Station, TX, USA).
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